THE EXPEDIENCY OF THE USE OF PIOGLITAZONE IN THE COMPLEX TREATMENT OF PSORIASIS IN PATIENTS WITH EXCESS BODY WEIGHT

  2. 2019
  3. THE EXPEDIENCY OF THE USE OF PIOGLITAZONE IN THE COMPLEX TREATMENT OF PSORIASIS IN PATIENTS WITH EXCESS BODY WEIGHT
Show/Download

Publication of the article:

«Bulletin of problems biology and medicine», 2019 Issue 2 Part 1, 150,

Yemchenko Ya., Ischeykin K., Kaidashev I.

THE EXPEDIENCY OF THE USE OF PIOGLITAZONE IN THE COMPLEX TREATMENT OF PSORIASIS IN PATIENTS WITH EXCESS BODY WEIGHT

About the author:

Yemchenko Ya., Ischeykin K., Kaidashev I.

Heading:

LITERATURE REVIEWS

Type of article:

Scentific article

Annotation:

Psoriasis is one of the most common chronic recurrent multifactorial diseases of the skin with a predominance of genetic bias, which is characterized by hyperproliferation of epidermal cells, a violation of the keratinization process against the background of inflammatory reactions in the dermis, as well as lesions of the nails, joints and scalp. According to the results of clinical and epidemiological research about 3-4% of the population of our planet has psoriasis, regardless of gender, age and ethnic group, while the share of this pathology in the overall structure of skin diseases reaches from 1% – to 40%, according to various authors. They consider psoriasis as a systemic disease with not only lesions of skin, but also joints and visceral involvement, as «psoriasis disease». The causes of psoriasis are immunological disorders and genetic defects. The data from many clinical studies show that there has been a recent increase in cases of comorbidity of psoriasis and obesity, leading to severe, atypical, disabling and resistant to dermatological treatment. All this greatly impairs the quality of life of patients, reduces the efficiency and social activity of patients with psoriasis, which determines not only the medical but also the social significance of the problem. Immunological disorders and genetic defects are the causes of psoriasis and abdominal obesity. The feature of the pathogenesis in patients with psoriasis with obesity, in contrast to patients without excessive body weight, is a statistically significant increase in and an increase in systemic cytokine proinflammatory potential. Therefore, the prospect of further research is a more in-depth study of the pathogenesis of comorbidity of psoriatic disease, which will reveal new targets for the treatment of this dermatosis.

Tags:

psoriasis, obesity, pathogenesis, systemic inflammation.

Bibliography:

 

  1. Yemchenko Ya, Іscheykіn K, Kaydashev І. Analіz zahvoryuvanostі ta poshirenostі na psorіaz v Ukraуnі ta v Poltavskіy oblastі. Aktualnі problemi suchasnoу medicini: Vіsnik Ukraуnskoу medichnoу stomatologіchnoу akademіі. 2014;3(47):72-6. [in Ukrainian].
  2. Yemchenko Ya. Stan sistemnogo zapalennya u hvorih psorіatichnoyu hvoroboyu serednogo stupenya tyazhkostі іz suputnіm metabolіchnim sindromom. Sіmeyna medicina. 2016;2:148-50. [in Ukrainian].
  3. Babak OYa, Yarmish NV, Shkolnik VV. Ozhirіnnya yak puskoviy mehanіzm adipocitokіnovogo kaskadu. Medicina transportu Ukraуni. 2012;2:94- 9. [in Ukrainian].
  4. Hayrutdinov VR. Rol immunnoy sistemyi kozhi v patogeneze psoriaza. Immunopatol, allergol, infektol. 2012;2:54-62. [in Russian].
  5. Yemchenko Ya. Riven pokaznykiv systemnoho zapalennia u khvorykh na psoriaz obtiazhenyi metabolichnym syndromom. Zhurnal dermatovenerolohii ta kosmetolohii imeni M.O. Torsueva. 2018;1(38):31-5. [in Ukrainian].
  6. Liu Z, Xiao T, Peng X. APPLs: More than just adiponectin receptor binding proteins. Cell Signal. 2017;32:76-84.
  7. Kaydashev IP. NF-kB-signalizaciya kak osnova razvitiya sistemnogo vospaleniya, insulinorezistentnosti, lipotoksichnosti, saharnogo diabeta 2-go tipa i ateroskleroza. Mezhdunarodnyy endokrinologicheskiy zhurnal. 2011;3(35):35-40. [in Russiаn].
  8. Banerjee A, Khemka VK, Roy D. Role of serum adiponectin and vitamin D in prediabetes and diabetes mellitus. Can. J. Diabetes. 2017;41(3):259- 65.
  9. Gasbarrino K, Zheng H, Hafiane A. Decreased adiponectin-mediated signaling through the AdipoR2 pathway is associated with carotid plaque instability. Stroke. 2017;48(4):915-24.
  10. Holland WL, Xia JY, Johnson JA. Inducible overexpression of adiponectin receptors highlight the roles of adiponectin-induced ceramidase signaling in lipid and glucose homeostasis. Mol. Metab. 2017;6(3):267-75.
  11. Liamyna S, Malushev Y. Poliaryzatsyia makrofahov v sovremennoi kontseptsyy formyrovanyia ymmunnoho otveta. Fundamentalnыe yssledovanyia. 2014;10(5):930-5. [in Russiаn].
  12. Suganami T, Tanimoto-Koyama K, Nishida J. Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acidinduced infl ammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol. 2007;27:84-91.
  13. Riestra P, Gebreab SY, Xu R. Gender-specific associations between ADIPOQ gene polymorphisms and adiponectin levels and obesity in the Jackson Heart Study cohort. BMC Med. Genet. 2015;16:65-9.
  14. Kaydashev IP. Izmenenie obraza zhizni, narushenie energeticheskogo metabolizma i sistemnoe vospalenie kak faktory razvitiya bolezney civilizacii. Ukraуnskiy medichniy chasopis. 2013;5:103-8. [in Russiаn].
  15. Kamylov FKh, Mufazalova NA, Kapuler OM. Tsytokinovyi dysbalans v ymmunopatoheneze psoriaza. Fundamentalni doslidzhennia. 2015;1:65- 71. [in Russian].
  16. Zhao W, Wu C, Li S, Chen X. Adiponectin protects palmitic acid induced endothelial inflammation and insulin resistance via regulating ROS/ IKKβ pathways. Cytokine. 2016;88:167-76.
  17. Schernthaner G. Craig Currie J, Schernthaner G. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care. 2013;36:2013-31.
  18. Savchenko LV, Kaydashev IP. Indyvidualnyi pidkhid do likuvannia khvorykh na ozhyrinnia KhOBL mozhe zmenshyty antropometrychni pokaznyky, riven systemnoho zapalennia ta polipshyty yakist zhyttia. Wiadomosci lekarskie. 2018;71(3):451-9. [in Ukrainian].
  19. Rasin MS, Rasin SM. Faktory transkripcii v centre sovremennoj biologii i mediciny. Receptory, aktiviruemye proliferatorami peroksisom. Likarska sprava. 2013;3:280-5. [in Russiаn].
  20. Vinnik NI, Kucenko LA. Effektivnost primeneniya pioglitazona v kompleksnoj terapii bolnyh ishemicheskoj boleznyu serdca na fone metabolicheskogo sindroma. Likarska sprava. 2011;3(4):67-73. [in Russiаn].

 

Publication of the article:

«Bulletin of problems biology and medicine» Issue 2 Part 1 (150), 2019 year, 18-21 pages, index UDK 616.517-056.5

DOI:

10.29254/2077-4214-2019-2-1-150-18-21

2019 Issue 2 Part 1, 150
01.03.2023
Was this article helpful?
23
1